|
1
|
Richardson PG, Barlogie B, Berenson J,
Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina
M, Alexanian R, et al: A phase 2 study of bortezomib in relapsed,
refractory myeloma. N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Richardson PG, Sonneveld P, Schuster MW,
Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D,
Lonial S, Goldschmidt H, et al: Bortezomib or high-dose
dexamethasone for relapsed multiple myeloma. N Engl J Med.
352:2487–2498. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dimopoulos M, Spencer A, Attal M, Prince
HM, Harousseau JL, Dmoszynska A, Miguel San J, Hellmann A, Facon T,
Foà R, et al: Lenalidomide plus dexamethasone for relapsed or
refractory multiple myeloma. N Engl J Med. 357:2123–2132. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Avet-Loiseau H, Leleu X, Roussel M, Moreau
P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat
L, Mathiot C, et al: Bortezomib plus dexamethasone induction
improves outcome of patients with t(4;14) myeloma but not outcome
of patients with del(17p). J Clin Oncol. 28:4630–4634. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang H, Trieu Y, Qi X, Xu W, Stewart KA
and Reece D: Bortezomib therapy response is independent of
cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Leuk Res. 31:779–782. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jagannath S, Richardson PG, Sonneveld P,
Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan
JM and Anderson KC: Bortezomib appears to overcome the poor
prognosis conferred by chromosome 13 deletion in phase 2 and 3
trials. Leukemia. 21:151–157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sagaster V, Ludwig H, Kaufmann H, Odelga
V, Zojer N, Ackermann J, Küenburg E, Wieser R, Zielinski C and
Drach J: Bortezomib in relapsed multiple myeloma: Response rates
and duration of response are independent of a chromosome
13q-deletion. Leukemia. 21:164–168. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuroda J, Shimura Y, Ohta K, Tanaka H,
Shibayama H, Kosugi S, Fuchida S, Kobayashi M, Kaneko H and Uoshima
N: Limited value of the international staging system for predicting
long-term outcome of transplant-ineligible, newly diagnosed,
symptomatic multiple myeloma in the era of novel agents. Int J
Hematol. 99:441–449. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tan D, Kim K, Kim JS, Eom HS, Teoh G, Ong
KH, Goh YT, Durie BG, Chng WJ and Lee JH: The impact of upfront
versus sequential use of bortezomib among patients with newly
diagnosed multiple myeloma (MM): A joint analysis of the Singapore
MM Study Group and the Korean MM Working Party for the Asian
myeloma network. Leuk Res. 37:1070–1076. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maltezas D, Dimopoulos MA, Katodritou I,
Repousis P, Pouli A, Terpos E, Panayiotidis P, Delimpasi S,
Michalis E and Anargyrou K: Re-evaluation of prognostic markers
including staging, serum free light chains or their ratio and serum
lactate dehydrogenase in multiple myeloma patients receiving novel
agents. Hematol Oncol. 31:96–102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harada H, Kawano MM, Huang N, Harada Y,
Iwato K, Tanabe O, Tanaka H, Sakai A, Asaoku H and Kuramoto A:
Phenotypic difference of normal plasma cells from mature myeloma
cells. Blood. 81:2658–2663. 1993.PubMed/NCBI
|
|
12
|
Kawano MM, Mihara K, Tsujimoto T, Huang N
and Kuramoto A: A new phenotypic classification of bone marrow
plasmacytosis. Int J Hematol. 61:179–188. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuroda Y, Sakai A, Okikawa Y, Munemasa S,
Katayama Y, Hyodo H, Imagawa J, Takimoto Y, Okita H, Ohtaki M and
Kimura A: The maturation of myeloma cells correlates with
sensitivity to chemotherapeutic agents. Int J Hematol. 81:335–341.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kumar S, Rajkumar SV, Kimlinger T, Greipp
PR and Witzig TE: CD45 expression by bone marrow plasma cells in
multiple myeloma: Clinical and biological correlations. Leukemia.
19:1466–1470. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Otsuyama K, Asaoku H and Kawano MM: An
increase in MPC-1− and MPC-1-CD45+ immature
myeloma cells in the progressive states of bone marrow
plasmacytosis: The revised phenotypic classification of monoclonal
marrow plasmacytosis (MOMP-2005). Int J Hematol. 83:39–43. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sahara N, Takeshita A, Shigeno K, Fujisawa
S, Takeshita K, Naito K, Ihara M, Ono T, Tamashima S, Nara K, et
al: Clinicopathological and prognostic characteristics of
CD56-negative multiple myeloma. Br J Haematol. 117:882–885. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sahara N and Takeshita A: Prognostic
significance of surface markers expressed in multiple myeloma: CD56
and other antigens. Leuk Lymphoma. 45:61–65. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang H, Samiee S and Yi QL: Prognostic
relevance of CD56 expression in multiple myeloma: A study including
107 cases treated with high-dose melphalan-based chemotherapy and
autologous stem cell transplant. Leuk Lymphoma. 47:43–47. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Moreau P, Robillard N, Avet-Loiseau H,
Pineau D, Morineau N, Milpied N, Harousseau JL and Bataille R:
Patients with CD45 negative multiple myeloma receiving high-dose
therapy have a shorter survival than those with CD45 positive
multiple myeloma. Haematologica. 89:547–551. 2004.PubMed/NCBI
|
|
20
|
Bene MC, Castoldi G, Knapp W, Ludwig WD,
Matutes E, Orfao A and van't Veer MB: Proposals for the
immunological classification of acute leukemias. European group for
the immunological characterization of leukemias (EGIL). Leukemia.
9:1783–1786. 1995.PubMed/NCBI
|
|
21
|
Iriyama N, Asou N, Miyazaki Y, Yamaguchi
S, Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Ohtake S, et
al: Normal karyotype acute myeloid leukemia with the
CD7+ CD15+ CD34+ HLA-DR
+ immunophenotype is a clinically distinct entity with a
favorable outcome. Ann Hematol. 93:957–563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iriyama N, Hatta Y, Takeuchi J, Ogawa Y,
Ohtake S, Sakura T, Mitani K, Ishida F, Takahashi M, Maeda T, et
al: CD56 expression is an independent prognostic factor for relapse
in acute myeloid leukemia with t(8;21). Leuk Res. 37:1021–1026.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tagoug I, Plesa A and Dumontet C:
Bortezomib influences the expression of malignant plasma cells
membrane antigens. Eur J Pharmacol. 706:11–16. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mahmoud MS, Ishikawa H, Fujii R and Kawano
MM: Induction of CD45 expression and proliferation in U-266 myeloma
cell line by interleukin-6. Blood. 92:3887–3897. 1998.PubMed/NCBI
|
|
26
|
Fujii R, Ishikawa H, Mahmoud MS, Asaoku H
and Kawano MM: MPC-1−CD49e− immature myeloma
cells include CD45+ subpopulations that can proliferate
in response to IL-6 in human myelomas. Br J Haematol. 105:131–140.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ishikawa H, Tsuyama N, Abroun S, Liu S, Li
FJ, Taniguchi O and Kawano MM: Requirements of src family kinase
activity associated with CD45 for myeloma cell proliferation by
interleukin-6. Blood. 99:2172–2181. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leonard WJ: Role of Jak kinases and STATs
in cytokine signal transduction. Int J Hematol. 73:271–277. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brown R, Yang S, Weatherburn C, Gibson J,
Ho PJ, Suen H, Hart D and Joshua D: Phospho-flow detection of
constitutive and cytokine-induced pSTAT3/5, pAKT and pERK
expression highlights novel prognostic biomarkers for patients with
multiple myeloma. Leukemia. 29:483–490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hundemer M, Klein U, Hose D, Raab MS,
Cremer FW, Jauch A, Benner A, Heiss C, Moos M, Ho AD and
Goldschmidt H: Lack of CD56 expression on myeloma cells is not a
marker for poor prognosis in patients treated by high-dose
chemotherapy and is associated with translocation t(11;14). Bone
Marrow Transplant. 40:1033–1037. 2007. View Article : Google Scholar : PubMed/NCBI
|
